Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 5th Floor 36 Dame Street, Dublin 2, Ireland

BillionerOfKing Sep. 16 at 2:53 AM

$AMRN Current Stock Price: $14.85 Contracts to trade: $15 AMRN Sep 19 2025 Call Entry: $0.48 Exit: $0.88 ROI: 85% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

BobGood Sep. 16 at 12:49 AM

$AMRN AD or any of Sarissa management members buys $AMRN from their own money?? Why not? Elon Musk just purchased over 2.56 million $TSLA shares in a Form 4 filing, worth more than $1 billion. He’s putting more of his own money on the line because he believes in Tesla’s mission. GL

1 · Reply

DoMoreCharity Sep. 15 at 10:35 PM

$AMRN https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176702443

0 · Reply

DoMoreCharity Sep. 15 at 10:17 PM

$AMRN https://www.mdpi.com/2673-396X/6/3/46

0 · Reply

declanaidan Sep. 15 at 8:46 PM

$AMRN Just saying, in April we had all the pundits saying the 20-1 r/s of Amarin stock was the final death knell. Pps then was 0.45 or current 9.30. Cuuently around 14.90, and very significant progress in execution setting this up for future, i.e into 2026. Risk reward here remains extraordinary

3 · Reply

ians Sep. 15 at 7:15 PM

$AMRN Good for Rybelsus reducing MACE by 14% vs. placebo for T2DM patients. 👍 But I remember Vascepa reduced MACE vs placebo by 25-28% for CVD patients 👏 This is why $AMRN mgmt. should consider doing a combo with a dual GLP-GIP agonist like VK2735 PO to see if there’s a further synergistic reduction in MACE with two assets that target different pathways. We’ll see soon enough Vk2735’s MACE reduction properties from the P3 SC trial. Food for thought for $VKTX mgmt. as well. ☘️💎 https://finance.yahoo.com/news/eu-approval-makes-novo-nordisk-120000931.html

0 · Reply

SanDiegoLiving Sep. 15 at 6:08 PM

$AMRN ⏳ Phase 3 Cancer Trial (EMT2): 75 Days to Lock 🔒 📅 University of Leeds said “1 year to go” in Nov ’24. Fast forward — it’s now Sept ’25 → just ~75 days remain until EMT2 wraps (Nov 30, 2025). At that point: ➡️ Patients finish dosing ➡️ Database locks in Leeds ➡️ Amarin + Barclays gain confidential access first 📰 Public results won’t hit until mid-2026, likely showcased at ASCO (American Society of Clinical Oncology) — the world’s #1 stage for Phase 3 cancer data. ✨ Why EMT2 matters: 🧬 4g/day pure EPA (pharma grade) 📊 Endpoints: survival + quality of life 🧪 Harvard microbiome sub-study completed 🏥 13 UK hospitals, max 4-yr dosing ⚖️ Bottom line: EMT2 is a pivotal oncology dataset weeks from lock. A positive result could position EPA as the first new supportive therapy in liver metastasis surgery. 👉 Do you guys want a deep dive on EMT2 and what’s at stake?

4 · Reply

PotatoSalad Sep. 15 at 5:54 PM

$AMRN left for dead by retail, tutes, and BP. Anyone with the means to extract that 'substantial value' everyone speaks of could do so but alas has not for years, even at fire sale levels. Sad!

1 · Reply

invest2992 Sep. 15 at 4:55 PM

$AMRN back to POS

0 · Reply

CEVIN Sep. 15 at 4:27 PM

$AMRN If only I had shorted this …..will this puppy ever reach $20.00 ($1.00 to long suffering retail pre R/S) Down yet again

0 · Reply

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 30, 2025, 8:30 AM EDT - 16 days ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Aug 25, 2025, 8:00 AM EDT - 21 days ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Jul 30, 2025, 2:06 PM EDT - 6 weeks ago

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 6 weeks ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 7 weeks ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jun 24, 2025, 7:05 AM EDT - 2 months ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

May 7, 2025, 11:01 AM EDT - 4 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:15 PM EDT - 4 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 5 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 14, 2025, 10:02 AM EDT - 5 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Apr 9, 2025, 7:30 AM EDT - 5 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 5 months ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 6 months ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 6 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 12, 2025, 10:30 AM EDT - 6 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:00 AM EST - 7 months ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 7 months ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 9 months ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 9 months ago

Amarin Appoints Peter Fishman Chief Financial Officer

Nov 19, 2024, 7:52 AM EST - 10 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Oct 30, 2024, 8:50 PM EDT - 11 months ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 1 year ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 10:43 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 1 year ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 10:18 AM EST - 1 year ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:00 AM EST - 1 year ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 8:00 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Jan 22, 2024, 7:30 AM EST - 1 year ago

Amarin Chairman & CEO Issue Letter to Shareholders

Jan 15, 2024, 3:06 AM EST - 1 year ago

Amarin: Sarissa Is Giving Me Hope Again

Jan 10, 2024, 6:40 PM EST - 1 year ago

Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

Jan 10, 2024, 7:00 AM EST - 1 year ago

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Dec 11, 2023, 8:00 AM EST - 1 year ago

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BillionerOfKing Sep. 16 at 2:53 AM

0 · Reply

BobGood Sep. 16 at 12:49 AM

1 · Reply

DoMoreCharity Sep. 15 at 10:35 PM

$AMRN https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176702443

0 · Reply

DoMoreCharity Sep. 15 at 10:17 PM

$AMRN https://www.mdpi.com/2673-396X/6/3/46

0 · Reply

declanaidan Sep. 15 at 8:46 PM

3 · Reply

ians Sep. 15 at 7:15 PM

0 · Reply

SanDiegoLiving Sep. 15 at 6:08 PM

4 · Reply

PotatoSalad Sep. 15 at 5:54 PM

$AMRN left for dead by retail, tutes, and BP. Anyone with the means to extract that 'substantial value' everyone speaks of could do so but alas has not for years, even at fire sale levels. Sad!

1 · Reply

invest2992 Sep. 15 at 4:55 PM

$AMRN back to POS

0 · Reply

CEVIN Sep. 15 at 4:27 PM

$AMRN If only I had shorted this …..will this puppy ever reach $20.00 ($1.00 to long suffering retail pre R/S) Down yet again

0 · Reply

SaltyNuts Sep. 15 at 4:05 PM

$AMRN Eventually once everything of value has been extracted this is going to sell for around $5 a share to some company that makes vitamins.

0 · Reply

lillylang Sep. 15 at 2:47 PM

$AMRN DoMorePumpin is the ultimate 👑🤡. 👑 🤡 👑 🤡 👑 🤡 👑 🤡 👑 🤡

1 · Reply

PotatoSalad Sep. 15 at 2:35 PM

$AMRN get comfy because once the BO window closes they're gonna go for a 3rd try w/ a new formulary. This crack mgmt team has you covered! Alex Denner for the win!

1 · Reply

DoMoreCharity Sep. 15 at 2:05 PM

$AMRN https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176699583

0 · Reply

RallyReaper Sep. 15 at 1:40 PM

$AMRN cmon Alex.. pull a musk..

0 · Reply

BobGood Sep. 15 at 1:37 PM

$AMRN $NVS & $GLUE entered into a licensing agreement valued at up to $5.7 billion. The collaboration aims to develop drugs for immune-mediated diseases. Wow... As usual and interestingly, $GLUE doesn't have any FDA approved drug, and many still under clinical trials !!! but still it's attractive to $NVS. Expecting a new theory today from our usual pumpers who link $NVS & $AMRN for the past several weeks... Hahaha.. Loosing patience.. GL

0 · Reply

NilsSB Sep. 15 at 10:47 AM

$AMRN I wonder if Novartis bought any of the companies that they aligned/partnered with in studies. If they did, how long did Novartis collaborate before purchase?

0 · Reply

lillylang Sep. 15 at 10:46 AM

$AMRN DoMorePumpin, DoMoreClowning. King Clown. 👑 🤡

1 · Reply

bennfine Sep. 15 at 10:45 AM

$AMRN what is that one share traded in premarket??

1 · Reply

DoMoreCharity Sep. 14 at 10:38 PM

$AMRN Sounds familiar… (ARIAD’s last partnership before buyout) https://investor.incyte.com/news-releases/news-release-details/incyte-and-ariad-announce-agreement-incyte-acquire-ariads

2 · Reply

DoMoreCharity Sep. 14 at 3:46 PM

$AMRN Sarissa will do it again, and even better.

1 · Reply

SanDiegoLiving Sep. 14 at 3:11 PM

$AMRN 🧩 Vazkepa’s EU-5 Endgame: France 🇫🇷 & Germany 🇩🇪 Loading 📅 Sept 9, 2025 → Recordati posts International Marketing Lead – Cardiovascular. 💊 Posting makes clear the role is Vazkepa-exclusive: “currently in launch phase and expanding its presence across Europe,” tasked with sustaining early-launch momentum and preparing "upcoming markets" for aligned launches. 📊 June 24 investor deck mapped Europe: ✅ 10 markets launched ⚖️ 4 mid-tier at final price talks 🔄 France & Germany flagged for re-submission — the only EU-5 holdouts. 🎯 Germany withdrew in 2022 after failed price talks; France blocked by negative ASMR. Both now “reloads.” This HQ-level hire looks designed to coordinate access + reimbursement firepower for their long-delayed entry — a signal these two are finally moving off the sidelines. 📌 Not routine staffing — a breadcrumb that Recordati is moving to complete Vazkepa’s EU-5 rollout. 🔗 https://careers.recordati.com/job/Hemel-Hempstead-International-Marketing-Lead%2C-Cardiovascular/1170157955/#

2 · Reply

Market Cap	310.45M
Revenue (ttm)	228.61M
Net Income (ttm)	-82.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-35.95%
Debt to Equity Ratio	0.00

Volume	67,000
Avg Vol	69,908
Day's Range	N/A - N/A
Shares Out	20.68M
Stochastic %K	35%
Beta	0.77
Analysts	Buy
Price Target	$11.00